Home » Stocks » OCX

OncoCyte Corporation (OCX)

Stock Price: $3.83 USD 0.06 (1.46%)
Updated May 13, 2021 4:00 PM EDT - Market closed
After-hours: $3.90 +0.08 (1.96%) May 13, 6:37 PM
Market Cap 349.35M
Revenue (ttm) 1.22M
Net Income (ttm) -29.93M
Shares Out 65.48M
EPS (ttm) -0.46
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 13
Last Price $3.83
Previous Close $3.77
Change ($) 0.06
Change (%) 1.46%
Day's Open 3.80
Day's Range 3.80 - 4.04
Day's Volume 405,516
52-Week Range 1.15 - 6.57

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

IRVINE, Calif., May 04, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the c...

1 week ago - GlobeNewsWire

OncoCyte (OCX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 week ago - Zacks Investment Research

DetermaIO now shown to predict immunotherapy response in four different tissue types suggesting potential pan-cancer applicability DetermaIO now shown to predict immunotherapy response in four different...

2 weeks ago - GlobeNewsWire

Oncocyte gains proprietary capabilities for immune therapy monitoring and transplant rejection testing, both from a standard blood sample

3 weeks ago - GlobeNewsWire

IRVINE, Calif., April 14, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the...

4 weeks ago - GlobeNewsWire

Achieved primary endpoint demonstrating significant correlation between DetermaIO and two-year overall survival rate to atezolizumab in metastatic bladder cancer

1 month ago - GlobeNewsWire

IRVINE, Calif., April 06, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the...

1 month ago - GlobeNewsWire

OncoCyte's pipeline of genomics-based cancer treatments bode well for its growth in the coming decade and OCX stock is already up 90% year-to-date. The post Best Stocks for 2021: OCX Got Off to a Fast S...

1 month ago - InvestorPlace

Enterprise Products Partners is an income powerhouse priced at 2011 levels. In a market favoring value stocks, EPD stock should enjoy 2021.

Other stocks mentioned: EPD, IZEA
1 month ago - InvestorPlace

OncoCyte (OCX) delivered earnings and revenue surprises of 10.00% and -52.10%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

DetermaRx commercialization momentum continues with 36% sample growth and 58% revenue growth compared to Q3 2020

1 month ago - GlobeNewsWire

Key Opinion Leaders in Oncology and Immune-Oncology Will Help Advance Development of Company's Diagnostic and Monitoring Tests Key Opinion Leaders in Oncology and Immune-Oncology Will Help Advance Devel...

2 months ago - GlobeNewsWire

IRVINE, Calif., March 03, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points acr...

2 months ago - GlobeNewsWire

IRVINE, Calif., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points acro...

2 months ago - GlobeNewsWire

IRVINE, Calif., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points acro...

2 months ago - GlobeNewsWire

IRVINE, Calif., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points acro...

3 months ago - GlobeNewsWire

The announcement of a new share issue usually drives a stock's price down, after all.

3 months ago - The Motley Fool

IRVINE, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points acro...

3 months ago - GlobeNewsWire

Oncocyte Corporation (NYSE: OCX) has agreed to acquire Chronix Biomedical, a privately held molecular diagnostics company, developing blood tests for cancer treatment and organ transplants. This agreeme...

3 months ago - Benzinga

Transaction includes proprietary IP and technology for blood-based immune therapy monitoring and for transplant rejection testing

3 months ago - GlobeNewsWire

OncoCyte Corp (NYSE: OCX) shares are advancing to their highest level since the middle of 2019 on above-average volume. Oncocyte said it has entered into definitive agreements with its two largest insti...

3 months ago - Benzinga

Offering Led by Current Shareholder and Healthcare Investor, Pura Vida Investments, Substantially Increasing Its Holdings

3 months ago - GlobeNewsWire

IRVINE, Calif., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points acro...

4 months ago - GlobeNewsWire

Which of our experts will win the best stocks contest? They're all betting on themes likely to dominate in 2021 and beyond.

Other stocks mentioned: BBBY, EPD, FVRR, IZEA, LMT, NIO, OR ...
4 months ago - InvestorPlace

One of the top stocks to buy for 2021 is OncoCyte, a molecular diagnostics company that offers genetic testing to physicians and patients. The post Best Stocks for 2021: OncoCyte (OCX) appeared first on...

4 months ago - InvestorPlace

Investors need to pay close attention to OncoCyte (OCX) stock based on the movements in the options market lately.

4 months ago - Zacks Investment Research

Shares of OCX stock are blasting off on Tuesday morning after a major company agreement with an important China-based biotech firm. The post OCX Stock: Why Shares of Biotech OncoCyte Are Skyrocketing To...

4 months ago - InvestorPlace

Shares of OncoCyte Corp. rocketed 63% on very heavy volume in premarket trading Tuesday, after the molecular diagnostics company announced overnight that it entered into an exclusive licensing agreement...

Other stocks mentioned: BNR
4 months ago - Market Watch

IRVINE, Calif., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points acro...

4 months ago - GlobeNewsWire

Physician researchers from Yale Cancer Center and University of California San Francisco (UCSF) to present on test performance in immunotherapy and chemotherapy selection Physician researchers from Yale...

5 months ago - GlobeNewsWire

Jaguar Health (NASDAQ: JAGX) shares are trading higher on Monday after the company announced its plans to develop and commercialize its Crofelemer. Jaguar Health is a commercial-stage pharmaceuticals co...

Other stocks mentioned: JAGX
5 months ago - Benzinga

IRVINE, Calif., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points acro...

5 months ago - GlobeNewsWire

Data demonstrate that DetermaIO™  can be run successfully using limited tissue from small biopsy specimens , overcoming the significant challenge s associated with tissue availability for molecular testing

5 months ago - GlobeNewsWire

OncoCyte Corporation (OCX) CEO Ronnie Andrews on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

Data show DetermaIO™ may help to select effective therapeutic options for immune checkpoint inhibitor (ICI) resistant patients with non-small cell lung cancer (NSCLC) and triple-negative breast cancer (...

6 months ago - GlobeNewsWire

Oncocyte named in Top 5 as one of Orange County's Best Places to Work in 2020 in its first year Oncocyte named in Top 5 as one of Orange County's Best Places to Work in 2020 in its first year

6 months ago - GlobeNewsWire

Testing volume for DetermaRx more than doubled in Q3 202 0

6 months ago - GlobeNewsWire

Chronix’s blood - based test monitors the effectiveness of immunotherapy drugs in clinical trials , and potentially in patients receiving immunotherapy treatment

7 months ago - GlobeNewsWire

IRVINE, Calif., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points a...

7 months ago - GlobeNewsWire

Pricing in line with comparable high-value molecular tests for oncology indications

8 months ago - GlobeNewsWire

Collaboration establishes an integrated platform for precision medicine clinical trials, combining Oncocyte’s proprietary molecular tests and fully certified pharma services lab with GRN’s nationwide ho...

8 months ago - GlobeNewsWire

IRVINE, Calif., Aug. 27, 2020 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points ac...

8 months ago - GlobeNewsWire

IRVINE, Calif., Aug. 13, 2020 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points ac...

9 months ago - GlobeNewsWire

Event to feature Dr. Naoto Ueno, study investigator and medical oncologist at the University of Texas MD Anderson Cancer Center

9 months ago - GlobeNewsWire

Oncocyte Corporation's (OCX) CEO Ronnie Andrews on Q2 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

OncoCyte (OCX) delivered earnings and revenue surprises of -27.27% and 257.50%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

9 months ago - Zacks Investment Research

 Secured National Medicare Reimbursement for DetermaRx™ Starting August 2020 with Final Medicare LCD from Palmetto GBA and Noridian Healthcare Solutions

9 months ago - GlobeNewsWire

Event to feature renowned lung cancer experts Dr. David Gandara and Dr. Johannes Kratz

9 months ago - GlobeNewsWire

IRVINE, Calif., July 20, 2020 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points ac...

9 months ago - GlobeNewsWire

Noridian's decision aligns with Palmetto GBA's final LCD for the test announced in April

9 months ago - GlobeNewsWire

About OCX

OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides custom drug target discovery; assay design, development, and validation; and clinical trial and other testing services for pharmaceutical companies. OncoCyte Corporation was founded in ... [Read more...]

Industry
Biotechnology
Founded
2009
Stock Exchange
NASDAQ
Ticker Symbol
OCX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for OncoCyte stock is "Buy." The 12-month stock price forecast is 7.71, which is an increase of 101.57% from the latest price.

Price Target
$7.71
(101.57% upside)
Analyst Consensus: Buy